Effect of Botulinum Toxin Type A Associated With Physical Therapy on Children With Spastic Cerebral Palsy
Primary Purpose
Cerebral Palsy, Spastic, Physical Therapy, Botulinum Toxin
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Botulinum toxin type A
Physical Therapy
Sponsored by
About this trial
This is an interventional treatment trial for Cerebral Palsy, Spastic
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of spastic Cerebral Palsy
- Clinical diagnosis of Dynamic equine feet
Exclusion Criteria:
- Use of phenol in the last 12 months
- Neurological blocks in the last 6 months
- Clinical diagnosis of structured orthopedic deformities with surgical indications
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Experimental group (EG)
Control group (CG)
Arm Description
The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
GC was treated with physiotherapy (stretching, balancing training, functional walking training).
Outcomes
Primary Outcome Measures
Severity of muscle hypertonia
The classification of hypertonia was performed by Modified Ashworth Scale
Functional balance
Functional balance was assessed using the Berg Balance Scale (BBS).
Secondary Outcome Measures
Functional mobility
Functional mobility was performed by The Timed Up and Go test (TUG test).
Functional performance
Functional performance was assessed using Pediatric Evaluation of Disability Inventory (PEDI).
Full Information
NCT ID
NCT03704155
First Posted
July 4, 2018
Last Updated
October 9, 2018
Sponsor
University of Nove de Julho
Collaborators
Claudia Santos Oliveira, Daniela Aparecida Biasotto-Gonzalez
1. Study Identification
Unique Protocol Identification Number
NCT03704155
Brief Title
Effect of Botulinum Toxin Type A Associated With Physical Therapy on Children With Spastic Cerebral Palsy
Official Title
Effect of Botulinum Toxin Type A Associated With Physical Therapy on the Functional Capacity of Children With Spastic Cerebral Palsy: A Randomized Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
January 2017 (Actual)
Primary Completion Date
May 2018 (Actual)
Study Completion Date
June 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Nove de Julho
Collaborators
Claudia Santos Oliveira, Daniela Aparecida Biasotto-Gonzalez
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Purpose: The aim of this study was investigate the effects of botulinum toxin type A (BoNT-A) associated with physical therapy on the functional capacity of children with spastic cerebral palsy (CP). Material and methods: Twenty-four children with spastic CP were concealed and randomly assigned to the Experimental Group (EG) consisting of 12 patients treated with BoNT-A and physical therapy and Control with 12 patients treated only with physical therapy. All participants were assessed through motor and functional scales (GMFM-88, Ashworth, Berg Balance Scale, TUG test and Pediatric Evaluation of Disability Inventory) at three different times: before and after 30 days of treatment as well as 3 months after the end of treatment.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy, Spastic, Physical Therapy, Botulinum Toxin
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomized controlled clinical trial
Masking
ParticipantOutcomes Assessor
Masking Description
Evaluator 1: triage, random draw of treatments to be performed; Evaluator 2: BoNT-A application; Evaluator 3: assessment data collection; Evaluator 4: physical therapy treatment. Evaluator 3 was blinded in relation to the groups.
Allocation
Randomized
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Experimental group (EG)
Arm Type
Experimental
Arm Description
The EG was treated with Botulinum toxin type A and physiotherapy (stretching, balancing training, functional walking training).
Arm Title
Control group (CG)
Arm Type
Active Comparator
Arm Description
GC was treated with physiotherapy (stretching, balancing training, functional walking training).
Intervention Type
Drug
Intervention Name(s)
Botulinum toxin type A
Intervention Description
Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
Intervention Type
Other
Intervention Name(s)
Physical Therapy
Intervention Description
Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.
The intervention protocol consisted of:
Passive stretching of lower limbs,
Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;
Strengthening of the antagonist muscles with the application of BoNT-A;
Static and dynamic balance training;
Up and down stairs;
Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion.
Primary Outcome Measure Information:
Title
Severity of muscle hypertonia
Description
The classification of hypertonia was performed by Modified Ashworth Scale
Time Frame
3 months
Title
Functional balance
Description
Functional balance was assessed using the Berg Balance Scale (BBS).
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Functional mobility
Description
Functional mobility was performed by The Timed Up and Go test (TUG test).
Time Frame
3 months
Title
Functional performance
Description
Functional performance was assessed using Pediatric Evaluation of Disability Inventory (PEDI).
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of spastic Cerebral Palsy
Clinical diagnosis of Dynamic equine feet
Exclusion Criteria:
Use of phenol in the last 12 months
Neurological blocks in the last 6 months
Clinical diagnosis of structured orthopedic deformities with surgical indications
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Botulinum Toxin Type A Associated With Physical Therapy on Children With Spastic Cerebral Palsy
We'll reach out to this number within 24 hrs